Computational prediction of oral drug absorption based on absorption rate constants in humans

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3674-3681

  Linnankoski, Johanna ^a   Mäkelä, Johanna M ^a,c   Ranta, Veli Pekka ^a   Urtti, Arto ^a,b   Yliperttula, Marjo ^b,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BUMETANIDE; CAFFEINE; CIMETIDINE; EFLORNITHINE; FAMOTIDINE; FELODIPINE; FUROSEMIDE; HYDROCORTISONE; IBUPROFEN; LAMIVUDINE; NEW DRUG; ONDANSETRON; OXPRENOLOL; PARACETAMOL; PHENAZONE; PINDOLOL; SCOPOLAMINE; SOTALOL; SUMATRIPTAN; TERBUTALINE; THEOPHYLLINE; VALPROIC ACID;

ACCURACY; ARTICLE; CORRELATION FUNCTION; DECONVOLUTION METHOD; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DETERMINATION; HUMAN; HYDROGEN BOND; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MATHEMATICAL MODEL; PHARMACOLOGICAL PARAMETERS; TECHNIQUE;

ADMINISTRATION, ORAL; COMPUTER SIMULATION; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745149302     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051231p     Document Type: Article

References (63)

1. Norinder, U.; Osterberg, T.; Artursson, P. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. Eur. J. Pharm. Sci. 1999, 8, 49-56.
2. Matsson, P.; Bergstrom, C. A.; Nagahara, N.; Tavelin, S.; Norinder, U.; Artursson, P. Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 2005, 48, 604-613.
3. Burton, P. S.; Goodwin, J. T.; Vidmar, T. J.; Amore, B. M. Predicting drug absorption: how nature made it a difficult problem. J. Pharmacol. Exp. Ther. 2002, 303, 889-895.
4. Wessel, M. D.; Jurs, P. C.; Tolan, J. W.; Muskal, S. M. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 1998, 38, 726-735.
5. Zhao, Y. H.; Abraham, M. H.; Le, J.; Hersey, A.; Luscombe, C. N.; Beck, G.; Sherborne, B.; Cooper, I. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 2002, 19, 1446-1457.
6. Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J.; Luscombe, C. N.; Butina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J. A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. 2001, 90, 749-784.
7. Norinder, U.; Osterberg, T.; Artursson, P. Theoretical calculation and prediction of Caco-2 cell permeability using MolSurf parametrization and PLS statistics. Pharm. Res. 1997, 14, 1786-1791.
8. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571.
9. Winiwarter, S.; Bonham, N. M.; Ax, F.; Hallberg, A.; Lennernas, H.; Karlen, A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 1998, 41, 4939-4949.
10. Winiwarter, S.; Ax, F.; Lennernas, H.; Hallberg, A.; Pettersson, C.; Karlen, A. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J. Mol. Graph. Model. 2003, 21, 273-287.
11. Osterberg, T.; Norinder, U. Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors. Eur. J. Pharm. Sci. 2001, 12, 327-337.
12. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J. Med. Chem. 2001, 44, 2490-7.
13. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target 1998, 6, 151-65.
14. Zhu, C.; Jiang, L.; Chen, T. M.; Hwang, K. K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential, Eur. J. Med. Chem. 2002, 37, 399-407.
15. Yazdanian, M.; Glynn, S. L.; Wright, J. L.; Hawi, A. Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 1998, 15, 1490-4.
16. Osterberg, T.; Svensson, M.; Lundahl, P. Chromatographic retention of drug molecules on immobilised liposomes prepared from egg phospholipids and from chemically pure phospholipids. Eur. J. Pharm. Sci. 2001, 12, 427-39.
17. van de Waterbeemd, H.; Smith, D. A.; Jones, B. C. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aided Mol. Des. 2001, 15, 273-86.
18. Can be found on the World Wide Web (http://www.cerep.fr/users/ pages/downloads/pharmacology.asp).
19. Austin, R. P.; Barton, P.; Cockroft, S. L.; Wenlock, M. C.; Riley, R. J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 2002, 30, 1497-503.
20. Can be found on the World Wide Web (http://www.acdlabs.com/products/ phys_chem_lab/logd/exp2.html).
21. Lombardo, F.; Obach, R. S.; Shalaeva, M. Y.; Gao, F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 2002, 45, 2867-76.
22. Yazdanian, M. Blood-brain barrier properties of human immunodeficiency virus antiretrovirals. J. Pharm. Sci. 1999, 88, 950-4.
23. Pascual, J.; Munoz, P. Correlation between lipophilicity and triptan outcomes. Headache 2005, 45, 3-6.
24. Goadsby, P. J. Sumatriptan is not the only analgesic used inappropriately. BMJ 1998, 317, 1016.
25. Ameer, B.; Divoll, M.; Abernethy, D. R.; Greenblatt, D. J.; Shargel, L. Absolute and relative bioavailability of oral acetaminophen preparations. J. Pharm. Sci. 1983, 72, 955-958.
26. Bochner, F.; Williams, D. B.; Morris, P. M.; Siebert, D. M.; Lloyd, J. V. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur. J. Clin. Pharmacol. 1988, 35, 287-294.
27. Danhof, M.; van Zuilen, A.; Boeijinga, J. K.; Breimer, D. D. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur. J. Clin. Pharmacol. 1982, 21, 433-441.
28. Mason, W. D.; Winer, N.; Kochak, G.; Cohen, I.; Bell, R. Kinetics and absolute bioavailability of atenolol. Clin. Pharmacol. Ther. 1979, 25, 408-415.
29. Holazo, A. A.; Colburn, W. A.; Gustafson, J. H.; Young, R. L.; Parsonnet, M. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J. Pharm. Sci. 1984, 73, 1108-1113.
30. Blanchard, J.; Sawers, S. J. The absolute bioavailability of caffeine in man. Eur. J. Clin. Pharmacol. 1983, 24, 93-98.
31. Walkenstein, S. S.; Dubb, J. W.; Randolph, W. C.; Westlake, W. J.; Stole, R. M.; Intoccia, A. P. Bioavailability of cimetidine in man. Gastroenterology 1978, 74, 360-365.
32. Haegele, K. D.; Alken, R. G.; Grove, J.; Schechter, P. J.; Koch-Weser, J. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin. Pharmacol. Ther. 1981, 30, 210-217.
33. Yeh, K. C.; Chremos, A. N.; Lin, J. H.; Constanzer, M. L.; Kanovsky, S. M.; Hucker, H. B.; Antonello, J.; Vlasses, P.; Ryan, J. R.; Williams, R. L. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm. Drug Dispos. 1987, 8, 549-560.
34. Edgar, B.; Regardh, C. G.; Lundborg, P.; Romare, S.; Nyberg, G.; Ronn, O. Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. Biopharm. Drug Dispos. 1987, 8, 235-248.
35. Waller, E. S.; Hamilton, S. F.; Massarella, J. W.; Sharanevych, M. A.; Smith, R. V.; Yakatan, G. J.; Doluisio, J. T. Disposition and absolute bioavailability of furosemide in healthy males. J. Pharm. Sci. 1982, 71, 1105-1108.
36. Derendorf, H.; Mollmann, H.; Earth, J.; Mollmann, C.; Tunn, S.; Krieg, M. Pharmacokinetics and oral bioavailability of hydrocortisone. J. Clin. Pharmacol. 1991, 31, 473-476.
37. Patel, R. B.; Rogge, M. C.; Selen, A.; Goehl, T. J.; Shah, V. P.; Prasad, V. K.; Welling, P. G. Bioavailability of hydrocortisone from commercial 20-mg tablets. J. Pharm. Sci. 1984, 73, 964-966.
38. Martin, W.; Koselowske, G.; Toberich, H.; Kerkmann, T.; Mangold, B.; Augustin, J. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm. Drug Dispos. 1990, 11, 265-278.
39. Lockwood, G. F.; Albert, K. S.; Gillespie, W. R.; Bole, G. G.; Harkcom, T. M.; Szpunar, G. J.; Wagner, J. G. Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships. Clin. Pharmacol. Ther. 1983, 34, 97-103.
40. Yuen, G. J.; Morris, D. M.; Mydlow, P. K.; Haidar, S.; Hall, S. T.; Hussey, E. K. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 1995, 35, 1174-1180.
41. Hsyu, P. H.; Pritchard, J. F.; Bozigian, H. P.; Lloyd, T. L.; Griffin, R. H.; Shamburek, R.; Krishna, G.; Barr, W. H. Comparison of the Pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm. Res. 1994, 11, 156-159.
42. Mason, W. D.; Winer, N. Pharmacokinetics of oxprenolol in normal subjects. Clin. Pharmacol. Ther. 1976, 20, 401-412.
43. Guerret, M.; Cheymol, G.; Aubry, J. P.; Cheymol, A.; Lavene, D.; Kiechel, J. R. Estimation of the absolute oral bioavailability of pindolol by two analytical methods. Eur. J. Clin. Pharmacol. 1983, 25, 357-359.
44. Putcha, L.; Cintron, N. M.; Tsui, J.; Vanderploeg, J. M.; Kramer, W. G. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm. Res. 1989, 6, 481-485.
45. Deneer, V. H.; Lie, A. H. L.; Kingma, J. H.; Proost, J. H.; Kelder, J. C.; Brouwers, J. R. Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. Br. J. Clin. Pharmacol. 1998, 45, 485-490.
46. Lacey, L. F.; Hussey, E. K.; Fowler, P. A. Single dose pharmacokinetics of Sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. 1995, 47, 543-548.
47. Borgstrom, L.; Nyberg, L.; Jonsson, S.; Lindberg, C.; Paulson, J. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br. J. Clin. Pharmacol. 1989, 27, 49-56.
48. Hendeles, L.; Weinberger, M.; Bighley, L. Absolute bioavailability of oral theophylline. Am. J. Hosp. Pharm. 1977, 34, 525-527.
49. Nitsche, V.; Mascher, H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 1982, 23, 153-162.
50. Chun, A. H.; Hoffman, D. J.; Friedmann, N.; Carrigan, P. J. Bioavailability of valproic acid under fasting/nonfasting regimens. J. Clin. Pharmacol. 1980, 20, 30-36.
51. Ozawa, N.; Shimizu, T.; Morita, R.; Yokono, Y.; Ochiai, T.; Munesada, K.; Ohashi, A.; Aida, Y.; Hama, Y.; Taki, K.; Maeda, K.; Kusuhara, H.; Sugiyama, Y. Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res. 2004, 21, 2133-2134.
52. Bodemar, G.; Norlander, B.; Walan, A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin. Pharmacokinet. 1981, 6, 306-15.
53. WinNonlin, version 4.0.1; Pharsight Corporation: Mountain View, CA.
54. ACD/Labs, version 6.0; Advanced Chemistry Development: Toronto, Canada.
55. ACD/ChemSketch, version 6.0; Advanced Chemistry Development: Toronto, Canada.
56. SAVOL; Tripos Inc.: St Louis, MO.
57. ClogP for Windows, version 2.0.0b; Biobyte; Claremont, CA.
58. Simca-P, version 10.5; Umetrics AB: Box 7960, SE-907 19 Umeå, Sweden.
59. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
60. Yu, L. X.; Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 1999, 186, 119-125.
61. GasfroPlus, version 3.3.0; Simulations Plus: Lancaster, CA.
62. Sagar, K. A.; Smyth, M. R. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J. Pharm. Biomed. Anal. 1999, 21, 383-392.
63. Lennernas, H.; Ahrenstedt, O.; Hallgren, R.; Knutson, L.; Ryde, M.; Paalzow, L. K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 1992, 9, 1243-51.